Investigational Drug Information for PF-04965842

What is the drug development status for PF-04965842?

PF-04965842 is an investigational drug.

There have been 25 clinical trials for PF-04965842. The most recent clinical trial was a Phase 3 trial, which was initiated on March 8^th 2018.

The most common disease conditions in clinical trials are Dermatitis, Atopic, Dermatitis, and Eczema. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are ninety-three US patents protecting this investigational drug and two hundred and thirty international patents.

Summary for PF-04965842

US Patents	93
International Patents	230
US Patent Applications	406
WIPO Patent Applications	248
Japanese Patent Applications	14
Clinical Trial Progress	Phase 3 (2018-03-08)
Vendors	49

Recent Clinical Trials for PF-04965842

Title	Sponsor	Phase
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis	Pfizer	Phase 2
Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants	Pfizer	Phase 1
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation	Pfizer	Phase 1

See all PF-04965842 clinical trials

Clinical Trial Summary for PF-04965842

Top disease conditions for PF-04965842

Top clinical trial sponsors for PF-04965842

See all PF-04965842 clinical trials

US Patents for PF-04965842

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
PF-04965842		Substituted indazoles for treating tendon and/or ligament injuries	NOVARTIS AG (Basel, CH)
PF-04965842		Aza-indazole compounds for use in tendon and/or ligament injuries	NOVARTIS AG (Basel, CH)
PF-04965842		Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof	Pfizer Inc. (New York, NY)

International Patents for PF-04965842

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
PF-04965842	Argentina	AR109688	2036-09-23
PF-04965842	Australia	AU2017332867	2036-09-23
PF-04965842	Brazil	BR112019005578	2036-09-23

PF-04965842 Development Update and Market Projection: Abrocitinib (Cibinqo)

Last updated: September 6, 2026

PF-04965842, now known as abrocitinib and marketed as Cibinqo, is an oral, selective Janus kinase 1 (JAK1) inhibitor developed by Pfizer for moderate-to-severe atopic dermatitis. The drug is commercially approved in the United States, European Union, Japan, and other markets. Its main commercial opportunity is as an oral alternative to injectable biologics such as dupilumab and tralokinumab, but its market share is constrained by JAK-class safety warnings, competition from upadacitinib, and the expanding biologic pipeline.

The base-case outlook is a specialized, durable atopic dermatitis product rather than a multibillion-dollar franchise. A reasonable global peak-sales range is approximately $500 million to $900 million, with upside above $1 billion requiring stronger use in adolescents, earlier-line oral treatment, and successful expansion into additional immune-mediated diseases.

What is the current development status of PF-04965842?

PF-04965842 is the development code for abrocitinib, an oral small-molecule inhibitor that preferentially inhibits JAK1. JAK1 signaling contributes to pathways activated by interleukins involved in atopic dermatitis, including IL-4, IL-13, IL-22, IL-31, and thymic stromal lymphopoietin.

Item	Current status
Generic name	Abrocitinib
Brand	Cibinqo
Developer	Pfizer
Drug class	Selective JAK1 inhibitor
Primary indication	Moderate-to-severe atopic dermatitis
FDA status	Approved
FDA approval date	Jan. 14, 2022
Approved US population	Adults and patients age 12 and older
Principal competitors	Dupixent, Rinvoq, Adbry, Ebglyss, topical therapies
Administration	Once-daily oral tablet
Main commercial issue	JAK boxed-warning restrictions and competitive positioning

The FDA approved Cibinqo for adults and adolescents age 12 years and older with refractory moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when those therapies are not advisable. The US label includes 50 mg, 100 mg, and 200 mg strengths, with lower-dose maintenance and dose-reduction options for certain patients. [1]

The European Medicines Agency authorized Cibinqo in 2021 for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. European use has been shaped by class-wide JAK risk restrictions and by the requirement to weigh cardiovascular, thrombotic, malignancy, and serious-infection risks. [2]

What clinical data support abrocitinib?

Abrocitinib has demonstrated rapid improvement in itch and skin clearance in Phase 3 atopic dermatitis trials. The pivotal JADE program included monotherapy and combination studies with topical corticosteroids.

JADE MONO-1 and JADE MONO-2

In the two pivotal monotherapy studies, patients receiving abrocitinib achieved higher rates of Investigator’s Global Assessment response and Eczema Area and Severity Index improvement than placebo-treated patients at week 12.

The most commercially relevant clinical attributes are:

• Rapid itch reduction, with some separation from placebo emerging within days.
• Efficacy at both 100 mg and 200 mg once-daily doses.
• Greater efficacy with the 200 mg dose, accompanied by greater safety and tolerability concerns.
• Use as oral induction therapy followed by lower-dose maintenance in some patients.

JADE COMPARE

JADE COMPARE compared abrocitinib with placebo and dupilumab in adults with moderate-to-severe atopic dermatitis. Abrocitinib, particularly at 200 mg, produced faster itch improvement and early skin-clearance benefits than dupilumab. Dupilumab remained a major long-term competitor because of its established safety profile, broad physician familiarity, and biologic efficacy.

The clinical differentiation is therefore front-loaded speed rather than clear long-term superiority. Abrocitinib can be attractive for patients who want oral treatment or rapid itch relief, while dupilumab retains advantages in treatment familiarity and long-term positioning.

JADE REGIMEN and long-term extension data

The JADE REGIMEN study evaluated withdrawal, dose reduction, and retreatment. The results supported maintenance with lower-dose abrocitinib after disease control and demonstrated that patients who relapsed after withdrawal could respond again upon retreatment. Long-term extension studies have provided continued exposure data, although treatment persistence remains sensitive to laboratory monitoring and JAK-class safety concerns. [3]

What is the FDA regulatory status of Cibinqo?

Cibinqo is FDA-approved but carries the class-wide JAK inhibitor boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The label recommends avoiding or carefully evaluating use in patients with risk factors such as smoking, cardiovascular disease, prior thrombosis, or malignancy.

The FDA label includes several restrictions:

• Cibinqo is generally positioned after failure or inadequate response to other systemic therapies, including biologics.
• It should not be combined with other JAK inhibitors, biologic immunomodulators, or potent immunosuppressants.
• Baseline and follow-up laboratory monitoring is required.
• Dose selection is influenced by age, kidney function, liver function, infection risk, and concomitant medications.
• The 200 mg dose is primarily an induction or high-need option, not the broad maintenance standard.

These restrictions reduce the addressable market compared with a label permitting unrestricted first-line systemic use. They also create a commercial disadvantage against biologics with less severe regulatory warnings.

What patents protect abrocitinib and when does it lose exclusivity?

Abrocitinib is protected by a US and international patent estate covering the active compound, pharmaceutical compositions, methods of treatment, and manufacturing or formulation aspects.

The principal US composition-of-matter protection is generally associated with an expiry period in the mid-2030s, subject to patent-term adjustment, patent-term extension, pediatric exclusivity, and the scope of any listed patents. The likely commercial protection window is longer than the basic FDA five-year new chemical entity exclusivity, which expired before or around the initial commercial launch period.

Protection category	Commercial relevance
Composition of matter	Primary barrier to generic abrocitinib
Pharmaceutical composition	May delay or complicate generic formulation entry
Method of treatment	Can support litigation if generic labeling induces patented use
Manufacturing process	May raise API production barriers but usually does not block all generic entry
Pediatric exclusivity	Potential six-month extension for qualifying listed patents
Regulatory exclusivity	Five-year NCE exclusivity from first US approval, subject to statutory timing

Cibinqo is an approved small molecule, not a biologic. It therefore faces eventual ANDA generic competition rather than biosimilar competition. The most important generic-entry risk is a Paragraph IV challenge to the composition-of-matter patent or to later-listed use and formulation patents.

What is the Orange Book status of Cibinqo?

Cibinqo is an FDA-approved small-molecule product eligible for Orange Book listing. The commercial importance of Orange Book entries depends on whether Pfizer has listed patents covering the active ingredient, drug product, or approved methods of use and whether those patents remain enforceable at the time of an ANDA filing.

A generic applicant may file:

• Paragraph I certification, stating no relevant patent information is listed.
• Paragraph II certification, stating that the patent has expired.
• Paragraph III certification, agreeing not to market until patent expiry.
• Paragraph IV certification, alleging that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV filing could trigger a 30-month stay of FDA approval if Pfizer files a timely infringement action. The strength of the core composition patent is likely to determine the earliest credible US generic launch date. Method-of-use patents are less robust if a generic label can omit the patented use, while formulation patents are most valuable when they cover commercially necessary dosage forms or release characteristics.

Which companies are challenging Cibinqo?

No major publicly reported US Paragraph IV litigation against Cibinqo had materially changed the US launch outlook through the available public record. The principal competitive pressure has come from marketed therapies rather than generic challengers.

Direct pharmaceutical competitors

Product	Company	Mechanism	Competitive position
Dupixent	Sanofi and Regeneron	IL-4R alpha antibody	Market leader in systemic atopic dermatitis
Rinvoq	AbbVie	Selective JAK1 inhibitor	Strongest oral JAK competitor
Adbry	LEO Pharma	IL-13 antibody	Biologic alternative
Ebglyss	Lilly and Almirall	IL-13 antibody	Growing biologic entrant
Nemolizumab	Galderma and partner companies	IL-31 receptor antagonist	Pruritus-focused emerging competitor
Topical JAK inhibitors	Multiple companies	JAK inhibition	Compete in less severe disease

Rinvoq is the closest pharmacologic competitor. Both products offer oral dosing and JAK1 selectivity, but Rinvoq has built a broader inflammatory-disease franchise and stronger commercial scale. Abrocitinib’s differentiation depends on rapid itch control, efficacy at the high dose, and Pfizer’s ability to maintain physician adoption despite class warnings.

What formulations are protected by abrocitinib patents?

The commercial product is an immediate-release oral tablet. The development and patent estate may cover:

• Abrocitinib active pharmaceutical ingredient.
• Solid oral dosage forms.
• Pharmaceutical compositions with defined excipients.
• Dosage regimens using 50 mg, 100 mg, or 200 mg strengths.
• Methods for treating moderate-to-severe atopic dermatitis.
• Dose reduction and maintenance regimens.
• Manufacturing processes and crystalline or salt forms, where applicable.

The immediate-release tablet is technically easier for generic manufacturers to reproduce than a complex injectable biologic or extended-release delivery system. Formulation patents may delay competition but are unlikely to provide the same barrier as a valid composition-of-matter patent.

What is the biosimilar and generic risk for abrocitinib?

There is no biosimilar risk because abrocitinib is a chemically synthesized small molecule. The relevant threat is generic substitution through the ANDA pathway.

Generic risk has four phases:

1. Patent challenge before core patent expiry.
2. Paragraph IV litigation and a potential 30-month stay.
3. At-risk launch after an adverse or favorable court decision.
4. Multi-generic erosion after final patent expiry.

An at-risk launch could produce rapid price compression because oral tablets have relatively simple manufacturing requirements. The erosion pattern would likely be faster than for an injectable biologic, although payer formulary rules and method-of-use labeling could affect substitution.

What patent litigation and settlement risks affect Cibinqo?

The principal litigation risk is future ANDA litigation rather than current product liability or biosimilar litigation. A generic company could challenge:

• Validity of the core compound patent.
• Obviousness of the claimed JAK1 inhibitor structure.
• Written description or enablement.
• Infringement of formulation or dosing claims.
• Enforceability based on patent prosecution conduct.

A settlement could establish a licensed generic entry date before the latest patent expiry. The value of a settlement would depend on the remaining US sales period, the number of potential generic challengers, and whether the agreement includes an authorized generic.

No publicly established settlement materially altered Cibinqo’s US exclusivity profile in the available record.

How does abrocitinib compare with Rinvoq and Dupixent?

Metric	Cibinqo	Rinvoq	Dupixent
Active ingredient	Abrocitinib	Upadacitinib	Dupilumab
Route	Oral	Oral	Subcutaneous injection
Primary mechanism	JAK1 inhibition	JAK1 inhibition	IL-4R alpha blockade
Itch response	Rapid	Rapid	Strong, usually less immediate than JAK inhibition
Boxed JAK warning	Yes	Yes	No JAK boxed warning
Administration burden	Daily tablet	Daily tablet	Periodic injection
Generic or biosimilar risk	Generic	Generic	Biosimilar
Commercial scale	Smaller	Larger	Much larger
Main advantage	Oral delivery and rapid itch relief	Broad immunology franchise and strong efficacy	Established safety, efficacy, and market access

Abrocitinib is commercially strongest in patients who prioritize an oral option, need rapid itch relief, or do not respond adequately to biologic therapy. It is weaker in patients with cardiovascular or thrombotic risk, in younger populations where long-term safety is closely scrutinized, and in payer settings that prefer established biologics.

What are the market projections for Cibinqo?

Pfizer’s public reporting has not positioned Cibinqo as a top-tier revenue driver comparable with Eliquis, Vyndaqel, Prevnar, or Ibrance. Its revenue trajectory depends on geographic expansion, oral JAK uptake, and the ability to compete with Rinvoq and Dupixent.

Base-case commercial forecast

Scenario	Peak global sales	Main assumptions
Bear case	$250 million-$450 million	JAK safety restrictions, limited payer access, strong Rinvoq and Dupixent competition
Base case	$500 million-$900 million	Durable use in moderate-to-severe disease, adolescent uptake, continued international expansion
Bull case	$1.0 billion-$1.5 billion	Broad oral first-line use, new indications, favorable comparative data, stronger persistence

The base case assumes that Cibinqo remains a meaningful but secondary systemic treatment. Its largest markets should be the United States, major European countries, Japan, and selected markets in Asia-Pacific and Latin America. Growth outside the US will depend on reimbursement, local regulatory approvals, and the relative pricing of oral JAK therapy versus biologics.

A new indication would be the clearest route to upside. Potential expansion areas historically associated with JAK1 programs include other inflammatory or pruritic diseases, but commercial valuation should not assume approval without positive late-stage data and regulatory acceptance. The atopic dermatitis franchise remains the most defensible basis for forecasting.

What generic launch scenarios exist for abrocitinib?

Early challenge scenario

A generic applicant files a Paragraph IV certification while the core patent remains in force. Pfizer litigates and obtains a 30-month stay. If the patent survives, generic entry is delayed until expiry or settlement.

Settlement scenario

Pfizer and the challenger agree to a licensed entry date before full patent expiry. This can reduce litigation cost but creates an earlier price-erosion date. An authorized generic could further reduce the challenger’s commercial opportunity.

At-risk launch scenario

The challenger launches before final resolution. If Pfizer ultimately prevails, damages and an injunction may follow. If Pfizer loses, multiple ANDA applicants can enter quickly, accelerating revenue erosion.

Post-expiry scenario

Once the core compound and key product patents expire, generic substitution is likely to be rapid. Abrocitinib’s simple oral formulation provides fewer manufacturing barriers than injectable biologics.

How strong is the patent estate for PF-04965842?

The estate is commercially meaningful but not structurally difficult to design around in the way a complex biologic manufacturing platform can be. Its strength is highest in the composition-of-matter claims and lower in secondary formulation, dosing, and method-of-use claims.

Patent strengths include:

• A small-molecule composition with a long initial protection period.
• Multiple dosage strengths supporting product-line protection.
• Clinical use claims tied to a large chronic disease population.
• Potential pediatric and patent-term adjustments.

Patent weaknesses include:

• Straightforward oral dosage-form manufacturing.
• Potential design-around options for generic labeling.
• Reduced leverage for method-of-use claims if noninfringing uses can be carved out.
• Exposure to standard small-molecule obviousness and enablement challenges.

Key Takeaways

• PF-04965842 is abrocitinib, marketed as Cibinqo.
• It is FDA-approved for patients age 12 and older with refractory moderate-to-severe atopic dermatitis.
• Its primary clinical advantage is rapid oral JAK1-mediated symptom and itch improvement.
• Rinvoq is the closest drug competitor; Dupixent remains the largest systemic benchmark.
• Cibinqo carries the JAK-class boxed warning, limiting first-line and high-risk patient use.
• The product faces generic, not biosimilar, competition.
• Core patent protection is expected to extend into the mid-2030s, subject to applicable patent-term adjustments and listed-patent scope.
• The base-case global peak-sales range is approximately $500 million to $900 million.
• Expansion beyond atopic dermatitis is the main upside variable.
• The principal downside risks are JAK safety restrictions, payer preference for biologics, and rapid generic erosion after core patent expiry.

FAQs

Is PF-04965842 the same as Cibinqo?

Yes. PF-04965842 is the development code for abrocitinib, which Pfizer markets under the brand name Cibinqo.

Is abrocitinib approved for alopecia areata?

Cibinqo’s established approval is for moderate-to-severe atopic dermatitis. Any additional indication requires separate regulatory approval and should not be included in the base commercial forecast without supporting regulatory action.

Is Cibinqo safer than Rinvoq?

Both are JAK inhibitors with class-wide warnings for serious infections, malignancies, cardiovascular events, and thrombosis. Comparative safety depends on dose, patient risk factors, treatment duration, and the specific adverse-event endpoint.

Can a generic company launch abrocitinib before patent expiry?

Potentially. A Paragraph IV applicant may challenge listed patents and launch at risk if the litigation outcome permits or if the applicant prevails. A settlement could also establish an earlier licensed entry date.

What is the biggest commercial threat to Cibinqo?

The largest current threat is not a biosimilar. It is competitive displacement by Dupixent and Rinvoq, combined with JAK safety restrictions and payer controls that limit oral therapy to later treatment lines.

References

1. U.S. Food and Drug Administration. (2022). Cibinqo (abrocitinib) prescribing information. FDA.

2. European Medicines Agency. (2021). Cibinqo: EPAR product information. EMA.

3. Bieber, T., Simpson, E. L., Silverberg, J. I., et al. (2021). Abrocitinib versus placebo or dupilumab for atopic dermatitis. The New England Journal of Medicine, 384(12), 1101-1112.

4. Simpson, E. L., Sinclair, R., Forman, S., et al. (2020). Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis. The Lancet, 396(10246), 255-266.

5. Pfizer Inc. (2024). Annual report 2023. Pfizer.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.